The following represents disclosure information provided by authors of this abstract. ASCO's Quality Care Symposium Planning Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).
Matti S. Aapro
Consultant or Advisory Role - Eisai; Helsinn Healthcare
Honoraria - Eisai; Helsinn Healthcare
Research Funding - Helsinn Healthcare
Giorgia Rossi
Employment or Leadership Position - Helsinn Healthcare
Giada Rizzi
Employment or Leadership Position - Helsinn Healthcare
Maria Elisa Borroni
Employment or Leadership Position - Helsinn Healthcare
Norman G. Nagl
Employment or Leadership Position - Eisai